Angiotensin receptor blockers and myocardial infarction

doi:10.1136/bmj.330.7502.1269

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Analysis of evidence is incomplete and inaccurate

John McMurray, professor of medical cardiology (j.mcmurray@bio.gla.ac.uk)1

¹Department of Cardiology, Western Infirmary, Glasgow G11 6NT

Editor—Verma and Strauss say that, compared with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers do not reduce (and may increase) the risk of myocardial infarction.1 Their claim represents an incomplete, inaccurate, and misleading “analysis” of the evidence.

They did not cite the two largest studies that randomised patients to an ACE inhibitor or angiotensin receptor blockers and had the statistical power to evaluate cardiovascular outcomes.2 3 These had twice …